Welcome to our dedicated page for Biomarin Pharmaceutical news (Ticker: BMRN), a resource for investors and traders seeking the latest updates and insights on Biomarin Pharmaceutical stock.
BioMarin Pharmaceutical Inc. develops and commercializes medicines for rare genetic diseases, with recurring news centered on commercial portfolio performance, regulatory approvals, clinical data and business development. Company updates commonly reference therapies for achondroplasia, phenylketonuria, hemophilia, mucopolysaccharidosis and lysosomal storage diseases, including VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
BioMarin news also covers financial results, guidance, acquisition integration, debt financing and governance changes. Clinical and regulatory announcements focus on genetically defined conditions, skeletal disorders, enzyme-based therapies and investigational rare-disease programs such as DMX-200 for focal segmental glomerulosclerosis.
BioMarin Pharmaceutical (NASDAQ:BMRN) has completed enrollment in a global Phase 2 study of vosoritide for treating achondroplasia in children under five. The 52-week, placebo-controlled trial involves about 70 participants and aims to assess safety and growth impact. Vosoritide targets the genetic cause of achondroplasia, addressing a significant treatment gap. The FDA is reviewing a New Drug Application for vosoritide, with a PDUFA date scheduled for August 20, 2021. Positive outcomes could lead to the first pharmacological treatment for this condition.
BioMarin Pharmaceutical (BMRN) reported financial results for Q4 and FY 2020, revealing total revenues of $452.1 million for Q4, nearly flat compared to Q4 2019. Full-year revenues rose 9% to $1.86 billion. Notably, Kuvan revenues fell by 27% due to generic competition, while Palynziq and Naglazyme saw significant growth. GAAP net income was $22.1 million for Q4, with a full-year net income of $859.1 million. The company anticipates 2021 total revenues between $1.75 billion and $1.85 billion, with expected GAAP net loss ranging from $130 million to $80 million. Positive clinical data for valoctocogene roxaparvovec and vosoritide highlight growth potential.
BioMarin Pharmaceutical (NASDAQ: BMRN) will participate in four upcoming virtual investor conferences. Live audio webcasts of the presentations can be accessed via their website, with archived versions available for a limited time post-conference. BioMarin is known for developing therapies for serious rare disorders, boasting a portfolio of six commercial products and several clinical candidates. Investors can find more information about the company and its innovations at www.biomarin.com.
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) has appointed Maykin Ho, Ph.D., a former Goldman Sachs partner, to its Board of Directors. Dr. Ho brings over 30 years of experience in healthcare and finance, aimed at supporting BioMarin's growth in addressing rare genetic diseases. The Chairman and CEO, Jean-Jacques Bienaimé, expressed confidence in Dr. Ho's expertise to enhance the company's strategic direction. BioMarin continues to develop innovative therapies with a portfolio of six commercialized products and numerous candidates in various stages.
Summary not available.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced a conference call scheduled for February 25, 2021, at 4:30 p.m. ET. CEO Jean-Jacques Bienaimé will discuss the company's fourth quarter and full year 2020 financial results alongside a business update. The call can be accessed via a live audio webcast on the BioMarin website. For U.S. participants, the dial-in number is (866) 502-9859, while international participants can dial (574) 990-1362, using Conference ID 6488682.
BioMarin Pharmaceutical (BMRN) announced positive topline results from its Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, a gene therapy for severe hemophilia A. The trial included 134 participants and found an 84% reduction in Annualized Bleeding Rate (ABR) after one year, with 80% of participants being bleed-free by week five. Factor VIII infusions also decreased by 99%. The FDA granted Breakthrough Therapy Designation, and BioMarin plans to submit data for marketing approval. The study represents a significant step toward a new treatment paradigm for hemophilia A.
BioMarin Pharmaceutical (NASDAQ: BMRN) has announced its participation in two upcoming virtual investor conferences. An audio webcast of these presentations will be available live, with access provided through the company's investor relations website. Additionally, an archived version will be accessible for a limited time post-conference. BioMarin specializes in innovative therapies for serious rare disorders, boasting a portfolio of six commercialized products along with several candidates in clinical stages.
BioMarin Pharmaceutical announced positive results from the Phase 3 extension study of vosoritide, a treatment for children with achondroplasia. Following two years of treatment, children showed maintained growth acceleration with a cumulative height gain of 3.52 cm compared to untreated subjects. The treatment was well tolerated, with 93% of participants remaining on it. Regulatory applications for vosoritide are under review by the FDA and EMA, with potential approval dates in August and the second half of 2021, respectively. This could mark the first therapy for achondroplasia in these regions.
BioMarin Pharmaceutical (NASDAQ: BMRN) announced its participation in two upcoming virtual investor conferences. An audio webcast of the presentations will be available for live access and later archived on the company's website. BioMarin focuses on developing innovative therapies for life-threatening rare disorders, boasting a portfolio that includes six commercialized products along with several clinical and pre-clinical candidates. For further details, please visit www.biomarin.com.